Testing a new medicine for kidney damage in chronic kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 27 or higher.
- You have reduced kidney function (based on a blood test).
- You have protein in your urine (a sign of kidney damage).
- You are not pregnant, breastfeeding, or planning to become pregnant, or you are using highly effective birth control.
- You have not taken a GLP-1 receptor agonist (like Ozempic, Wegovy, or Mounjaro) in the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of an investigational medicine (NNC0537-1482) to see how it moves through the body in people with different levels of kidney function. It may help researchers understand how the drug is processed so it can be dosed safely in future studies.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study tests whether taking two medications together—finerenone and semaglutide—can help protect kidney function in people with obesity and chronic kidney disease who have protein in their urine. The goal is to see if this combination is safe and effective for slowing kidney damage.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This trial tests a new oral medication (DWP16001) for people with type 2 diabetes who also have moderate kidney problems. It aims to see if the drug is safe and helps control blood sugar while protecting kidney function.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.